Agilent Technologies and Accelrys announce software licensing agreement and technology alliance

Agilent Technologies Inc. and Accelrys Inc., a wholly owned subsidiary of Pharmacopeia Inc., today announced a software licensing agreement and technology alliance expected to result in software to assist pharmaceutical and biotech professionals in the development of more effective drugs.

Under the terms of the agreement, Agilent will license the use of Accelrys' Viewer ActiveX Control for 3D visualization of molecular structures. The Viewer ActiveX Control will be integrated into the recently released Agilent Synapsia Informatics Workbench, and will enable scientists and technicians in the pharmaceutical and biotech industry to visualize and share molecular information in a clear and consistent manner across the pharmaceutical value chain. It is expected to further enhance the collaborative knowledge synthesizing capability of Agilent's Informatics software, and therefore help accelerate decision-making in the development of more effective drugs.

Accelrys' Viewer ActiveX Control visualization capabilities will be incorporated into new Agilent informatics software products that will include the following features:

  • line, stick, ball and stick, scaled ball and stick, CPK, and polyhedron atom display styles;
  • protein display styles including C-alpha, ribbon, tube, and schematic;
  • orthographic or perspective viewing projection; and
  • lighting color, shading, and direction options.

"This agreement will enhance Agilent's wide-range of informatics software products used for data management, gene expression, proteomics, drug and disease discovery research," said Chris van Ingen, senior vice president of Agilent's life sciences and chemical analysis business. "We are pleased to be working with Accelrys to access the best visualization tools available and further develop software products that reduce the bottleneck of data manipulation and analysis."

"This agreement demonstrates our companies' common vision of providing open environments that enable users to select the best tools to suit their research needs," said Dr. Scott Kahn, general manager and senior vice president, Accelrys Life Science. "Through this offering, we aim to provide a level of interconnectivity between Agilent and Accelrys products that will enable them to freely exchange molecular and genetic data. We believe that the future of accelerated pharmaceutical research is exemplified by the productivity gains inherent in this approach."

Quelle: Agilent Technologies

» alle Nachrichten dieser Firma